DRUG Valuation

Bright Minds Biosciences Inc

Add to Watchlist

Advanced Chart

41.820

0(0.000%)1D

Overview
Forecast
Valuation
Earnings

DRUG Relative Valuation

DRUG's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, DRUG is overvalued; if below, it's undervalued.

Historical Valuation

Bright Minds Biosciences Inc (DRUG) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.71. The fair price of Bright Minds Biosciences Inc (DRUG) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：41.82

Fair

-10.82

Trailing

Forward

-3.95

EV/EBITDA

Bright Minds Biosciences Inc. (DRUG) has a current EV/EBITDA of -3.95. The 5-year average EV/EBITDA is -0.99. The thresholds are as follows: Strongly Undervalued below -6.11, Undervalued between -6.11 and -3.55, Fairly Valued between 1.57 and -3.55, Overvalued between 1.57 and 4.13, and Strongly Overvalued above 4.13. The current Forward EV/EBITDA of -3.95 falls within the Undervalued range.

-6.17

EV/EBIT

Bright Minds Biosciences Inc. (DRUG) has a current EV/EBIT of -6.17. The 5-year average EV/EBIT is -2.44. The thresholds are as follows: Strongly Undervalued below -14.95, Undervalued between -14.95 and -8.69, Fairly Valued between 3.82 and -8.69, Overvalued between 3.82 and 10.07, and Strongly Overvalued above 10.07. The current Forward EV/EBIT of -6.17 falls within the Historic Trend Line -Fairly Valued range.

0.00

Bright Minds Biosciences Inc. (DRUG) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.

-5.35

P/OCF

Bright Minds Biosciences Inc. (DRUG) has a current P/OCF of -5.35. The 5-year average P/OCF is -2.68. The thresholds are as follows: Strongly Undervalued below -16.38, Undervalued between -16.38 and -9.53, Fairly Valued between 4.17 and -9.53, Overvalued between 4.17 and 11.02, and Strongly Overvalued above 11.02. The current Forward P/OCF of -5.35 falls within the Historic Trend Line -Fairly Valued range.

-4.98

P/FCF

Bright Minds Biosciences Inc. (DRUG) has a current P/FCF of -4.98. The 5-year average P/FCF is -1.62. The thresholds are as follows: Strongly Undervalued below -9.49, Undervalued between -9.49 and -5.55, Fairly Valued between 2.32 and -5.55, Overvalued between 2.32 and 6.26, and Strongly Overvalued above 6.26. The current Forward P/FCF of -4.98 falls within the Historic Trend Line -Fairly Valued range.

Bright Minds Biosciences Inc (DRUG) has a current Price-to-Book (P/B) ratio of 8.20. Compared to its 3-year average P/B ratio of 9.04 , the current P/B ratio is approximately -9.34% higher. Relative to its 5-year average P/B ratio of 7.11, the current P/B ratio is about 15.27% higher. Bright Minds Biosciences Inc (DRUG) has a Forward Free Cash Flow (FCF) yield of approximately -1.86%. Compared to its 3-year average FCF yield of -36.94%, the current FCF yield is approximately -94.97% lower. Relative to its 5-year average FCF yield of -35.11% , the current FCF yield is about -94.71% lower.

8.20

P/B

Median3y

9.04

Median5y

7.11

-1.86

FCF Yield

Median3y

-36.94

Median5y

-35.11

Competitors Valuation Multiple

The average P/S ratio for DRUG's competitors is 17.76, providing a benchmark for relative valuation. Bright Minds Biosciences Inc Corp (DRUG) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

DRUG.O

Bright Minds Biosciences Inc

Prothena Corporation PLC

Performance Decomposition

Market capitalization of DRUG increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of DRUG in the past 1 year is driven by Unknown.